Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung disease

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 837-846

  Little, Frédéric ^a   Cruikshank, William ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma therapeutics; Atopy; CD4; Cytokines; Immunomodulation; Interleukin 16

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 16; PEPTIDE DERIVATIVE;

ALLERGIC ASTHMA; ATOPIC DERMATITIS; ATOPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DOWN REGULATION; ENTERITIS; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; NONHUMAN; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ANIMALS; ANTIGENS, CD4; ASTHMA; CHEMOTACTIC FACTORS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-16; LUNG DISEASES; MICE; MODELS, BIOLOGICAL; PEPTIDES; T-LYMPHOCYTES; TH2 CELLS;

EID: 3042601164     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.837     Document Type: Review

References (71)

1. CRUIKSHANK W, CENTER DM: Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J. Immunol. (1982) 128:2569-2574. Initial description of LCF/IL-16: one of the first described T cell-specific chemoattractants.
2. LABERGE S, CRUIKSHANK WW, KORNFELD H, CENTER DM: Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage. J. Immunol. (1995) 155:2902-2910
3. RUMSAENG V, CRUIKSHANK WW, FOSTER B et al.: Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J. Immunol. (1997) 159:2904-2910.
4. LIM KG, WAN HC, BOZZA PT et al.: Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J. Immunol. (1996) 156:2566-2570.
5. SCIAKY D, BRAZER W, CENTER DM, CRUIKSHANK WW, SMITH TJ: Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3- dependent mechanism. J. Immunol. (2000) 164:3806-3814.
6. LABERGE S, ERNST P, GHAFFAR O et al.: Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am. J. Respir. Cell Mol. Biol. (1997) 17:193-202. In situ and immunohistochemical localisation of IL-16 to epithelium in asthma.
7. KORNFELD H, CRUIKSHANK WW: Prospects for IL-16 in the treatment of AIDS. Expert Opin. Biol. Ther. (2001) 1:425-432.
8. BUSSE WW, LEMANSKE RF JR: Asthma. N. Engl. J. Med. (2001) 344:350-362. Detailed review of asthma pathophysiology with applicable clinical and basic science.
9. + T cells into Th1 and Th2.
10. CHER DJ, MOSMANN TR: Two types of murine helper T cell done. II. Delayed-type hypersensitivity is mediated by TH1 dones. J. Immunol. (1987) 138:3688-3694.
11. CHERWINSKI HM, SCHUMACHER JH, BROWN KD, MOSMANN TR: Two types of mouse helper T cell done. III. Further differences in lymphokine synthesis between Th1 and Th2 dones revealed by RNA hybridization, functionally monospecific bioassays, and monodonal antibodies. J. Exp. Med. (1987) 166:1229-1244.
12. DEL PRETE GF, DE CARLI M, MASTROMAURO C et al.: Purified protein derivative of Mycobacterium tuberculosis and excretoty-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest (1991) 88:346-350.
13. YAMAMURA M, UYEMURA K, DEANS RJ et al.: Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 254:277-279.
14. SZABO SJ, KIM ST, COSTA GL, ZHANG X, FATHMAN CG, GLIMCHER LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100:655-669. Molecular mechanisms [14-16] at transcriptional level of reciprocal inhibition of Th1 and Th2 cell differentiation and cytokine profiles.
15. ZHENG W, FLAVELL RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 89:587-596.
16. HO IC, LO D, GLIMCHER LH: c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J. Exp. Med. (1998) 188:1859-1866.
17. TEMANN UA, GEBA GP, RANKIN JA, FLAVELL RA: Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J. Exp. Med. (1998) 188:1307-1320.
18. ZHU Z, HOMER RJ, WANG Z et al.: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. Clin. Invest. (1999) 103:779-788.
19. BARNES PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. (2003) 14:511-522.
20. AKDIS CA, KUSSEBI F, PULENDRAN B et al.: Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur. J. Immunol. (2003) 33:2717-2726. Use of synthetic bacterial wall products to inhibit Th2 responses by 'promoting' Th1 enviroment.
21. LYNCH EA, HEIJENS CA, HORST NF, CENTER DM, CRUIKSHANK WW: Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J. Immunol. (2003) 171:4965-4968. Provides mechanistic explanation for IL-16-related downregulation of Th2 responses not related to inhibition of T cell activation.
22. KIM HS: Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet. Cell Genet. (1999) 84:93.
23. BANNERT N, KURTH R, BAIER M: The gene encoding mouse interleukin-16 consists of seven exons and maps to chromosome 7 D2-D3. Immunogenetics (1999) 49:704-706.
24. KURSCHNER C, YUZAKI M: Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J. Neurosci. (1999) 19:7770-7780. Desciption of longer IL-16 precursor located in CNS.
25. BANNERT N, VOLLHARDT K, ASOMUDDINOV B et al.: PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J. Biol. Chem. (2003) 278:42190-42199.
26. BANNERT N, AVOTS A, BAIER M, SERFLING E, KURTH R: GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes. Proc. Natl. Acad. Sci. USA (1999) 96:1541-1546. Characterisation of proximal IL-16 promoter regulation in the immortalised Jurkat T cell line.
27. CHUPP GL, WRIGHT EA, WU D et al.: Tissue and T cell distribution of precursor and mature IL-16. J. Immunol. (1998) 161:3114-3119.
28. KASER A, DUNZENDORFER S, OFFNER FA et al.: A role for IL-16 in the cross-talk between dendritic cells and T cells. J. Immunol. (1999) 163:3232-3238.
29. LABERGE S, CRUIKSHANK WW, BEER DJ, CENTER DM: Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J. Immunol. (1996) 156:310-315.
30. ZHANG Y, CENTER DM, WU DM et al.: Processing and activation of pro-interleukin-16 by caspase-3. J. Biol. Chem. (1998) 273:1144-1149.
31. MUHLHAHN P, ZWECKSTETTER M, GEORGESCU J et al.: Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat. Struct. Biol. (1998) 5:682-686.
32. CENTER DM, CRUIKSHANK WW, ZHANG Y: Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J. Immunol. (2004) 172:1654-1660.
33. WILSON KC, CRUIKSHANK WW, CENTER DM, ZHANG Y: Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry (2002) 41:14306-14312.
34. ZHANG Y, KORNFELD H, CRUIKSHANK WW, KIM S, REARDON CC, CENTER DM: Nuclear translocation of the N-terminal prodomain of interleukin-16. J. Biol. Chem. (2001) 276:1299-1303.
35. LIU Y, CRUIKSHANK WW, O'LOUGHLIN T, O'REILLY P, CENTER DM, KORNFELD H: Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J. Biol. Chem. (1999) 274:23387-23395. Demonstration that binding site of IL-16 on the D4 domain of CD4 maps to the sequence required for CD4 autoaggregation during T cell activation [36].
36. CRUIKSHANK WW, CENTER DM, NISAR N et al.: Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc. Natl. Acad. Sci. USA (1994) 91:5109-5113. Cloning of LCF/IL-16 and requirement for CD4 expression in IL-16-mediated T cell responses.
37. KEANE J, NICOLL J, KIM S et al.: Conservation of structure and function between human and murine IL-16. J. Immunol. (1998) 160:5945-5954.
38. BANNERT N, ADLER HS, WERNER A, BAIER M, KURTH R: Molecular cloning and sequence analysis of interleukin 16 from nonhuman primates and from the mouse. Immunogenetics (1998) 47:390-397.
39. MATHY NL, BANNERT N, NORLEY SG, KURTH R. Cutting edge: CD4 is not required for the functional activity of IL-16. J. Immunol. (2000) 164:4429-4432.
40. YANG J, LIU CQ: Interaction between human interleukin-16 and CD4 receptor of HIV-1. Acta Pharmacol. Sin. (2000) 21:547-553.
41. KITCHEN SG, LAFORGE S, PATEL VP, KITCHEN CM, MICELI MC, ZACK JA: Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood (2002) 99:207-212.
42. CRUIKSHANK WW, GREENSTEIN JL, THEODORE AC, CENTER DM: Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J. Immunol. (1991) 146:2928-2934.
43. RYAN TC, CRUIKSHANK WW, KORNFELD H, COLLINS TL, CENTER DM: The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J. Biol. Chem. (1995) 270:17081-17086.
44. PARADA NA, CRUIKSHANK WW, DANIS HL, RYAN TC, CENTER DM: IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell. Immunol. (1996) 168:100-106.
45. NICOLL J, CRUIKSHANK WW, BRAZER W, LIU Y, CENTER DM, KORNFELD H: Identification of domains in IL-16 critical for biological activity. J. Immunol. (1999) 163:1827-1832. Identification of 4-amino acid RRKS sequence that mediates bioactivity.
46. WU H, KWONG PD, HENDRICKSON WA: Dimeric association and segmental variability in the structure of human CD4. Nature (1997) 387:527-530.
47. GRATTON S, HAUGHN L, SEKALY RP, JULIUS M: The extracellular domain of CD4 regulates the initiation of T cell activation. Mol. Immunol. (2000) 37:213-219.
48. CICALA C, ARTHOS J, RUIZ M et al.: Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J. Immunol. (1999) 163:420-426. Demonstration that HIV gp120 can elicit signalling of CD4 and CCR5.
49. MASHIKIAN MV, RYAN TC, SEMAN A, BRAZER W, CENTER DM, CRUIKSHANK WW: Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. J. Immunol. (1999) 163:3123-3130. Two articles [49,50] that describe IL-16-mediated chemokine receptor desensitisation and, therefore, regulation of inflammatory cell chemoattraction.
50. VAN DRENTH C, JENKINS A, LEDWICH L et al.: Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J. Immunol. (2000) 165:6356-6363.
51. STAUDINGER R, PHOGAT SK, XIAO X, WANG X, DIMITROV DS, ZOLLA-PAZNER S: Evidence for CD4-enchanced signaling through the chemokine receptor CCR5. J. Biol. Chem. (2003) 278:10389-10392.
52. WANG X, STAUDINGER R: Interaction of soluble CD4 with the chemokine receptor CCR5. Biochem. Biophys. Res. Commun. (2003) 307:1066-1069.
53. WONG M, UDDIN S, MAJCHRZAK B et al: Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J. Biol. Chem. (2001) 276:11427-11431.
54. THEODORE AC, CENTER DM, NICOLL J, FINE G, KORNFELD H, CRUIKSHANK WW: CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. (1996) 157:1958-1964.
55. CRUIKSHANK WW, LIM K, THEODORE AC et al.: IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J. Immunol. (1996) 157:5240-5248. Initial detailed description of IL-16-induced T cell anergy in selling setting of antigen stimulation.
56. DE BIE JJ, JONKER EH, HENRICKS PA et al.: Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin. Exp. Allergy (2002) 32(11):1651-1658. In vivo characterisations of immunomodulatory effect of systemic IL-16 and aerosolised peptide on allergic airway response.
57. DE BIE JJ, HENRICKS PA, CRUIKSHANK WW, HOFMAN G, NIJKAMP FP, VAN OOSTERHOUT AJ: Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model. Eur. J. Pharmacol. (1999) 383:189-196. See [56].
58. BLASCHKE S, SCHULZ H, SCHWARZ G, BLASCHKE V, MULLER GA, REUSS-BORST M: Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J. Rheumatol. (2001) 28:12-21.
59. KEATES AC, CASTAGLIUOLO I, CRUIKSHANK WW et al.: Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology (2000) 119:972-982.
60. CHENG G, ARIMA M, HONDA K et al.: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med. (2002) 166:409-416.
61. PINSONNEAULT S, EL BASSAM S, MAZER B, CRUIKSHANK WW, LABERGE S: IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J. Allergy Clin. Immunol. (2001) 107:477-482.
62. CRUIKSHANK WW, LONG A, TARPY RE et al.: Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am. J. Respir. Cell Mol. Biol. (1995) 13:738-747.
63. MASHIKIAN MV, TARPY RE, SAUKKONEN JJ et al.: Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J. All. Clin. Immunol. (1998) 101:786-792.
64. LABERGE S, PINSONNEAULT S, VARGA EM et al.: Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J. Allergy Clin. Immunol. (2000) 106:293-301.
65. BLEASE K, LEWIS A, RAYMON HK: Emerging treatments for asthma. Expert Opin. Emerg. Drugs (2003) 8:71-81.
66. CHUNG KF: Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr. Opin. Investig. Drugs (2003) 4:1320-1326.
67. BORISH LC, NELSON HS, LANZ MJ et al.: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (1999) 160:1816-1823.
68. BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. (2001) 107:963-970.
69. FLOOD-PAGE P, MENZIES-GOW A, PHIPPS S et al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest (2003) 112:1029-1036.
70. MENZIES-GOW A, FLOOD-PAGE P, SEHMI R et al.: Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. (2003) 111:714-719.
71. LUKACS NW, BERLIN A, SCHOLS D, SKERLJ RT, BRIDGER GJ: AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol. (2002) 160:1353-1360.